Rare blood clot events more common among women receiving AstraZeneca Covid-19 vaccine, EMA says

Zachary Brennan

Senior Editor

The EMA is sticking with its statement that AstraZeneca’s Covid-19 vaccine is safe and effective, but the agency also discussed new data showing that younger …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rare blood clot events more common among women receiving AstraZeneca Covid-19 vaccine, EMA says

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

Apollo makes a deal worth up to $926M; Abeona resubmits gene therapy

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Rare blood clot events more com­mon among women re­ceiv­ing As­traZeneca Covid-19 vac­cine, EMA says

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Rare blood clot events more common among women receiving AstraZeneca Covid-19 vaccine, EMA says

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

Apollo makes a deal worth up to $926M; Abeona resubmits gene therapy

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?